JPWO2019200172A5 - - Google Patents

Info

Publication number

JPWO2019200172A5

JPWO2019200172A5 JP2020555340A JP2020555340A JPWO2019200172A5 JP WO2019200172 A5 JPWO2019200172 A5 JP WO2019200172A5 JP 2020555340 A JP2020555340 A JP 2020555340A JP 2020555340 A JP2020555340 A JP 2020555340A JP WO2019200172 A5 JPWO2019200172 A5 JP WO2019200172A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

compound

cancer

wing segment

composition according

Prior art date

2023-03-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 87
• 239000002777 nucleoside Substances 0.000 claims description 55
• 201000011510 cancer Diseases 0.000 claims description 33
• 125000003835 nucleoside group Chemical group 0.000 claims description 33
• 108091034117 Oligonucleotide Proteins 0.000 claims description 30
• 206010028980 Neoplasm Diseases 0.000 claims description 26
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 24
• 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 22
• 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 22
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 16
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 14
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 10
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 8
• 206010025323 Lymphomas Diseases 0.000 claims description 8
• 208000034578 Multiple myelomas Diseases 0.000 claims description 8
• 208000000389 T-cell leukemia Diseases 0.000 claims description 8
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 8
• 206010042971 T-cell lymphoma Diseases 0.000 claims description 8
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 8
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
• 210000004027 cell Anatomy 0.000 claims description 8
• 230000002489 hematologic effect Effects 0.000 claims description 6
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 5
• 206010027476 Metastases Diseases 0.000 claims description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
• 229940104302 cytosine Drugs 0.000 claims description 5
• 230000009401 metastasis Effects 0.000 claims description 5
• 230000004614 tumor growth Effects 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims 17
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 4
• 239000002953 phosphate buffered saline Substances 0.000 claims 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
• 239000003085 diluting agent Substances 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
• 230000009702 cancer cell proliferation Effects 0.000 claims 1
• 239000005549 deoxyribonucleoside Substances 0.000 claims 1
• 210000005260 human cell Anatomy 0.000 claims 1
• 230000003834 intracellular effect Effects 0.000 claims 1
• 230000036210 malignancy Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 22
• 150000003833 nucleoside derivatives Chemical class 0.000 description 16
• 230000002401 inhibitory effect Effects 0.000 description 9
• 239000002773 nucleotide Substances 0.000 description 8
• 125000003729 nucleotide group Chemical group 0.000 description 8
• 230000000692 anti-sense effect Effects 0.000 description 7
• 239000000203 mixture Substances 0.000 description 7
• 230000010261 cell growth Effects 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• IHLOTZVBEUFDMD-UUOKFMHZSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,2-dioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 IHLOTZVBEUFDMD-UUOKFMHZSA-N 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 159000000000 sodium salts Chemical group 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1